Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report
This case report investigates the potential use of metabolism as a sensitive biomarker in monitoring the effectiveness of anti-amyloid therapy in a patient with mild cognitive impairment due to early Alzheimer's disease. The study centers around a 74-year-old male patient treated with aducanuma...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | NeuroImage: Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666956024000096 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045688832851968 |
|---|---|
| author | Kirk C. Wilhelmsen Pierre-François D’Haese Marc W. Haut Gary D. Marano Rashi I. Mehta Xiaofei Wang Melanie Ward Mark Miller Umer Najib R. Osvaldo Navia Cierra M. Keith Ali Rezai |
| author_facet | Kirk C. Wilhelmsen Pierre-François D’Haese Marc W. Haut Gary D. Marano Rashi I. Mehta Xiaofei Wang Melanie Ward Mark Miller Umer Najib R. Osvaldo Navia Cierra M. Keith Ali Rezai |
| author_sort | Kirk C. Wilhelmsen |
| collection | DOAJ |
| description | This case report investigates the potential use of metabolism as a sensitive biomarker in monitoring the effectiveness of anti-amyloid therapy in a patient with mild cognitive impairment due to early Alzheimer's disease. The study centers around a 74-year-old male patient treated with aducanumab, a monoclonal antibody developed for anti-amyloid therapy. Alongside an expected decline in cerebral amyloid monitored using PET amyloid tracers, we observed significant improvements in the patient's brain metabolic activity, measured via 18-fluorodeoxyglucose positron emission tomography (FDG PET). Despite limitations posed by the single-patient case study, the findings invite further research and consider the utilization of FDG PET as a surrogate for clinically meaningful changes in the treatment of early Alzheimer's disease. These findings suggest the potential for more personalized and effective therapeutic interventions. |
| format | Article |
| id | doaj-art-4e1c3f937dda4de0b3e0ee7cbed38c03 |
| institution | DOAJ |
| issn | 2666-9560 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | NeuroImage: Reports |
| spelling | doaj-art-4e1c3f937dda4de0b3e0ee7cbed38c032025-08-20T02:54:39ZengElsevierNeuroImage: Reports2666-95602024-06-014210020310.1016/j.ynirp.2024.100203Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case reportKirk C. Wilhelmsen0Pierre-François D’Haese1Marc W. Haut2Gary D. Marano3Rashi I. Mehta4Xiaofei Wang5Melanie Ward6Mark Miller7Umer Najib8R. Osvaldo Navia9Cierra M. Keith10Ali Rezai11Rockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Departments of Neurology of West Virginia University, Morgantown, West Virginia, USA; Corresponding author. WVU Department of Neurology, WVU Rockefeller Neuroscience Institute, 33 Medical Center Drive, PO Box 9301, 26506, Morgantown, West Virginia, USA.Rockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Neuroradiology of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Behavioral Medicine and Psychiatry of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Radiology of West Virginia University, Morgantown, West Virginia, USA; Medicine of West Virginia University, Morgantown, West Virginia, USANeuroradiology of West Virginia University, Morgantown, West Virginia, USA; Radiology of West Virginia University, Morgantown, West Virginia, USARadiology of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Departments of Neurology of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Behavioral Medicine and Psychiatry of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Departments of Neurology of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Medicine of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Behavioral Medicine and Psychiatry of West Virginia University, Morgantown, West Virginia, USARockefeller Neuroscience Institute of West Virginia University, Morgantown, West Virginia, USA; Neurosurgery of West Virginia University, Morgantown, West Virginia, USAThis case report investigates the potential use of metabolism as a sensitive biomarker in monitoring the effectiveness of anti-amyloid therapy in a patient with mild cognitive impairment due to early Alzheimer's disease. The study centers around a 74-year-old male patient treated with aducanumab, a monoclonal antibody developed for anti-amyloid therapy. Alongside an expected decline in cerebral amyloid monitored using PET amyloid tracers, we observed significant improvements in the patient's brain metabolic activity, measured via 18-fluorodeoxyglucose positron emission tomography (FDG PET). Despite limitations posed by the single-patient case study, the findings invite further research and consider the utilization of FDG PET as a surrogate for clinically meaningful changes in the treatment of early Alzheimer's disease. These findings suggest the potential for more personalized and effective therapeutic interventions.http://www.sciencedirect.com/science/article/pii/S2666956024000096Alzheimer's diseaseMetabolismBiomarkersFDG PETAmyloid |
| spellingShingle | Kirk C. Wilhelmsen Pierre-François D’Haese Marc W. Haut Gary D. Marano Rashi I. Mehta Xiaofei Wang Melanie Ward Mark Miller Umer Najib R. Osvaldo Navia Cierra M. Keith Ali Rezai Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report NeuroImage: Reports Alzheimer's disease Metabolism Biomarkers FDG PET Amyloid |
| title | Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report |
| title_full | Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report |
| title_fullStr | Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report |
| title_full_unstemmed | Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report |
| title_short | Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report |
| title_sort | metabolism as a biomarker for treatment success in anti amyloid therapy a case report |
| topic | Alzheimer's disease Metabolism Biomarkers FDG PET Amyloid |
| url | http://www.sciencedirect.com/science/article/pii/S2666956024000096 |
| work_keys_str_mv | AT kirkcwilhelmsen metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT pierrefrancoisdhaese metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT marcwhaut metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT garydmarano metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT rashiimehta metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT xiaofeiwang metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT melanieward metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT markmiller metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT umernajib metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT rosvaldonavia metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT cierramkeith metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport AT alirezai metabolismasabiomarkerfortreatmentsuccessinantiamyloidtherapyacasereport |